MicroRNA-383-5p regulation of NADPH oxidase 4 alleviates hemorrhagic transformation and improves acute outcomes after endovascular recanalization in acute ischemic stroke.
QY, J., W, Q., JK, Z., ZX, C., QY, C., CL, L., & ZS, S. (2026). MicroRNA-383-5p regulation of NADPH oxidase 4 alleviates hemorrhagic transformation and improves acute outcomes after endovascular recanalization in acute ischemic stroke.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1870493
QY J, W Q, JK Z, ZX C, QY C, CL L, et al. MicroRNA-383-5p regulation of NADPH oxidase 4 alleviates hemorrhagic transformation and improves acute outcomes after endovascular recanalization in acute ischemic stroke.. Frontiers in immunology. 2026; doi: 10.3389/fimmu.2026.1870493
QY J, W Q, JK Z, et al. MicroRNA-383-5p regulation of NADPH oxidase 4 alleviates hemorrhagic transformation and improves acute outcomes after endovascular recanalization in acute ischemic stroke.[J]. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1870493.
@article{qy2026,
author = {Jiang QY and Qin W and Zhuang JK and Chen ZX and Chen QY and Li CL and Shi ZS},
title = {MicroRNA-383-5p regulation of NADPH oxidase 4 alleviates hemorrhagic transformation and improves acute outcomes after endovascular recanalization in acute ischemic stroke.},
journal = {Frontiers in immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1870493},
note = {PMID: 42421953},
}
TY - JOUR AU - Jiang QY AU - Qin W AU - Zhuang JK AU - Chen ZX AU - Chen QY AU - Li CL AU - Shi ZS TI - MicroRNA-383-5p regulation of NADPH oxidase 4 alleviates hemorrhagic transformation and improves acute outcomes after endovascular recanalization in acute ischemic stroke. T2 - Frontiers in immunology PY - 2026 DO - 10.3389/fimmu.2026.1870493 AN - PMID:42421953 ER -
BACKGROUND: Hemorrhagic transformation (HT) following reperfusion therapy is associated with poor outcomes in patients with acute ischemic stroke. Here, we determined the role of microRNA-383-5p (miR-383-5p) in alleviating HT-associated injury using models of middle cerebral artery occlusion (MCAO) and oxygen-glucose deprivation/reoxygenation (OGD/R). METHODS: Two hundred and five hyperglycemic rats were used to establish a model of HT induced by mechanical recanalization after 5 hours of MCAO, followed by 3 and 6 hours of recanalization; then, miR-383-5p agomir was administered intravenously before recanalization. Analysis involved brain water content; hemorrhage severity; infarct volume; blood-brain barrier (BBB) disruption; neuronal apoptosis, reactive oxygen species (ROS) production; along with the expression levels of miR-383-5p, NADPH oxidase 4 (NOX4), interleukin 1 beta (IL-1β), and BBB-associated proteins. The expression of miR-383-5p and NOX4 was also evaluated in neurons after OGD/R, whereas neuronal injury and ROS production were assessed following intervention with miR-383-5p and small interfering RNA. RESULTS: In the MCAO model, intravenous administration of miR-383-5p agomir increased miR-383-5p and suppressed NOX4 upregulation in peri-infarct tissue and in brain microvascular endothelial cells, neurons, and astrocytes, as demonstrated by immunohistochemical fluorescent staining. Increased levels of miR-383-5p alleviated brain edema, infarct volume, and the severity of hemorrhage; reduced ROS overproduction, neuronal apoptosis, and IL-1β overexpression in astrocytes; and preserved BBB integrity after mechanical recanalization following ischemia, thereby improving acute neurological outcomes assessed at 3 and 6 hours after recanalization. Following OGD/R, reduced miR-383-5p and increased NOX4 expression were detected in neurons. Elevated miR-383-5p levels reduced neuronal injury, ROS overproduction, and NOX4 overexpression in OGD/R-treated neurons. NOX4 was confirmed as a direct target gene of miR-383-5p. CONCLUSIONS: MiR-383-5p alleviated oxidative stress injury, neuronal apoptosis, inflammation, and preserved BBB integrity by regulating NOX4. Therefore, miR-383-5p represents a potential therapeutic target to reduce HT and improve outcomes during the acute phase of recanalization after endovascular treatment for acute ischemic stroke.